Literature DB >> 25503829

Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.

Carsten Saft1, Rainer Hoffmann, Katrin Strassburger-Krogias, Thomas Lücke, Saskia H Meves, Gisa Ellrichmann, Christos Krogias.   

Abstract

In Huntington's disease (HD), a neurodegenerative-inherited disease, chorea as the typical kind of movement disorder is described. Beside chorea, however, all other kinds of movement disturbances, such as bradykinesia, dystonia, tremor or myoclonus can occur. Aim of the current study was to investigate alterations in the echogenicity of basal ganglia structures in different Huntington's disease phenotypes. 47 patients with manifest and genetically confirmed HD were recruited. All participants underwent a thorough neurological examination. According to a previously described method, classification into predominantly choreatic, mixed or bradykinetic-rigid motor phenotypes was performed depending on subscores of the Unified Huntington's Disease Rating Scale. In addition, findings in juvenile HD were compared to adult HD. Transcranial sonography was performed by investigators blinded to clinical classification. There were no significant differences in basal ganglia echogenicities between the three phenotypes. Size of echogenic area of substantia nigra (SN) correlated positively with CAG repeat and bradykinesia subscore, and negatively with age of onset and chorea subscore. Comparing juvenile and adult HD subtypes, SN hyperechogenicity was significantly more often detectable in the juvenile form (100 vs. 29.3 %, p = 0.002). Regarding echogenicity of caudate or lentiform nuclei, no significant differences were detected. HD patients with the juvenile variant exhibit marked hyperechogenicity of substantia nigra. No significant differences in basal ganglia echogenicities between predominantly choreatic, mixed or bradykinetic-rigid motor phenotypes were detected.

Entities:  

Mesh:

Year:  2014        PMID: 25503829     DOI: 10.1007/s00702-014-1335-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  47 in total

Review 1.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

2.  Basal ganglia hyperechogenicity does not distinguish between patients with primary dystonia and healthy individuals.

Authors:  Johann Hagenah; Inke R König; Charlotte Kötter; Günter Seidel; Christine Klein; Norbert Brüggemann
Journal:  J Neurol       Date:  2010-11-02       Impact factor: 4.849

3.  Biomarkers for PD: How can we approach complexity?

Authors:  Daniela Berg; Oliver Bandmann
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

4.  Relationship of substantia nigra echogenicity and motor function in elderly subjects.

Authors:  D Berg; C Siefker; P Ruprecht-Dörfler; G Becker
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

5.  Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.

Authors:  Carsten Saft; Jochen Zange; Jürgen Andrich; Klaus Müller; Katrin Lindenberg; Bernhard Landwehrmeyer; Matthias Vorgerd; Peter H Kraus; Horst Przuntek; Ludger Schöls
Journal:  Mov Disord       Date:  2005-06       Impact factor: 10.338

Review 6.  Transcranial sonography in dystonia.

Authors:  Alexandra Gaenslen
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

7.  Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease.

Authors:  Sven H Stüwe; Oliver Goetze; Carsten Lukas; Peter Klotz; Rainer Hoffmann; Matthias Banasch; Michael Orth; Wolfgang E Schmidt; Ralf Gold; Carsten Saft
Journal:  Neurology       Date:  2013-02-06       Impact factor: 9.910

8.  Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

Authors:  Daniela Berg; Stefanie Behnke; Klaus Seppi; Jana Godau; Stefanie Lerche; Philipp Mahlknecht; Inga Liepelt-Scarfone; Christoph Pausch; Niko Schneider; Alexandra Gaenslen; Kathrin Brockmann; Karin Srulijes; Heiko Huber; Isabel Wurster; Heike Stockner; Stefan Kiechl; Johann Willeit; Arno Gasperi; Klaus Fassbender; Thomas Gasser; Werner Poewe
Journal:  Mov Disord       Date:  2012-10-31       Impact factor: 10.338

Review 9.  Huntington's disease: a clinical review.

Authors:  Raymund A C Roos
Journal:  Orphanet J Rare Dis       Date:  2010-12-20       Impact factor: 4.123

10.  Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

Authors:  Carsten Saft; Thorsten Lauter; Peter H Kraus; Horst Przuntek; Juergen E Andrich
Journal:  BMC Neurol       Date:  2006-02-28       Impact factor: 2.474

View more
  2 in total

Review 1.  Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.

Authors:  Andrea Pilotto; Rezzak Yilmaz; Daniela Berg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

2.  Alterations in transcranial sonography among Huntington's disease patients with psychiatric symptoms.

Authors:  Grzegorz Witkowski; Katarzyna Jachinska; Iwona Stepniak; Karolina Ziora-Jakutowicz; Halina Sienkiewicz-Jarosz
Journal:  J Neural Transm (Vienna)       Date:  2020-04-13       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.